Literature DB >> 28625570

Progress toward Fulfilling the Potential of Immunomodulation in Childhood Neurodegeneration?

Jonathan D Cooper1, Hemanth R Nelvagal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28625570      PMCID： PMC5542794          DOI： 10.1016/j.ymthe.2017.06.006

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  14 in total

1.  Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis.

Authors:  Shannon L Macauley; Marie S Roberts; Andrew M Wong; Francesca McSloy; Adarsh S Reddy; Jonathan D Cooper; Mark S Sands
Journal:  Ann Neurol       Date:  2012-02-24       Impact factor: 10.422

2.  An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis.

Authors:  Shannon L Macauley; Andrew M S Wong; Charles Shyng; David P Augner; Joshua T Dearborn; Yewande Pearse; Marie S Roberts; Stephen C Fowler; Jonathan D Cooper; D Martin Watterson; Mark S Sands
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

Review 3.  Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).

Authors:  Jacqueline A Hawkins-Salsbury; Jonathan D Cooper; Mark S Sands
Journal:  Biochim Biophys Acta       Date:  2013-06-06

Review 4.  Towards a new understanding of NCL pathogenesis.

Authors:  Jonathan D Cooper; Marta A Tarczyluk; Hemanth R Nelvagal
Journal:  Biochim Biophys Acta       Date:  2015-05-28

5.  Immunosuppression alters disease severity in juvenile Batten disease mice.

Authors:  Sabrina S Seehafer; Denia Ramirez-Montealegre; Andrew Ms Wong; Chun-Hung Chan; Julian Castaneda; Michael Horak; Sarah M Ahmadi; Ming J Lim; Jonathan D Cooper; David A Pearce
Journal:  J Neuroimmunol       Date:  2011-01       Impact factor: 3.478

6.  Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).

Authors:  Megan E Bosch; Amy Aldrich; Rachel Fallet; Jessica Odvody; Maria Burkovetskaya; Kaitlyn Schuberth; Julie A Fitzgerald; Kevin D Foust; Tammy Kielian
Journal:  J Neurosci       Date:  2016-09-14       Impact factor: 6.167

7.  Immune cells perturb axons and impair neuronal survival in a mouse model of infantile neuronal ceroid lipofuscinosis.

Authors:  Janos Groh; Thomas G Kühl; Chi Wang Ip; Hemanth R Nelvagal; Sarmi Sri; Steven Duckett; Myriam Mirza; Thomas Langmann; Jonathan D Cooper; Rudolf Martini
Journal:  Brain       Date:  2013-03-12       Impact factor: 13.501

8.  Sialoadhesin promotes neuroinflammation-related disease progression in two mouse models of CLN disease.

Authors:  Janos Groh; Eliana Ribechini; David Stadler; Tim Schilling; Manfred B Lutz; Rudolf Martini
Journal:  Glia       Date:  2016-01-17       Impact factor: 7.452

9.  AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease.

Authors:  Martin L Katz; Luis Tecedor; Yonghong Chen; Baye G Williamson; Elena Lysenko; Fred A Wininger; Whitney M Young; Gayle C Johnson; Rebecca E H Whiting; Joan R Coates; Beverly L Davidson
Journal:  Sci Transl Med       Date:  2015-11-11       Impact factor: 17.956

10.  Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3).

Authors:  Amy Aldrich; Megan E Bosch; Rachel Fallet; Jessica Odvody; Maria Burkovetskaya; Kakulavarapu V Rama Rao; Jonathan D Cooper; Arlene V Drack; Tammy Kielian
Journal:  Ann Neurol       Date:  2016-11-23       Impact factor: 10.422
View more
  1 in total

1.  Combined Anti-inflammatory and Neuroprotective Treatments Have the Potential to Impact Disease Phenotypes in Cln3 -/- Mice.

Authors:  Marta A Tarczyluk-Wells; Christoph Salzlechner; Allison R Najafi; Ming J Lim; David Smith; Frances M Platt; Brenda P Williams; Jonathan D Cooper
Journal:  Front Neurol       Date:  2019-09-11       Impact factor: 4.003
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.